Fig. 2.

Efficacy of tocilizumab infusion in inhibiting the signs and symptoms of RA patients in daily clinical practice. Values of DAS28 (a–c) and HAQ-DI (d–f) from baseline to 24 weeks after initiation of tocilizumab therapy are shown: a, d all 229 cases, b, e patients who concomitantly received methotrexate (MTX; filled diamond, n = 127) or did not receive MTX (filled square, n = 102), c, f patients who previously received anti-tumor necrosis factor (TNF) therapy (filled diamond, n = 144) or did not previously receive anti-TNF therapy (filled square, n = 85). Data were analyzed by the LOCF method. a, d At all time points after 4 weeks, values are significantly decreased from baseline (P < 0.00001), b, e at all time points after 4 weeks, values of patients who concomitantly received MTX are significantly lower than those of patients who did not (P < 0.00001), c, f at all timepoints after 4 weeks, values did not differ between patients who did and did not previously receive anti-TNF therapy